Clinical Trials Logo

Filter by:
NCT ID: NCT05988918 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Start date: April 19, 2024
Phase: Phase 2
Study type: Interventional

This protocol will enroll patients with pancreatic adenocarcinoma and adenosquamous carcinoma (Cohort 1), gastrointestinal/pancreatic neuroendocrine neoplasms with Ki-67 > 20% (Cohort 2) and neuroendocrine prostate carcinoma (Cohort 3)). Each cohort will have its own interim analysis after enrollment of 10 patients. Subjects will be given a one-month (28 day) supply of study drug (ESK981). Subjects will be instructed to take 4 capsules, with or without food, once per day for 5 consecutive calendar days, then take a drug holiday for 2 consecutive days before repeating the 5 days on-2 days off cycle in sets of 4 weeks or 28 calendar days. Subjects will be asked to keep a pill diary noting the date they take their study drug.

NCT ID: NCT05988892 Recruiting - Cancer Clinical Trials

A Study of Physical Activity in Cancer Survivors

Start date: June 23, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if increasing physical activity (PA) will increase physical functioning, as measured by cardiovascular endurance, muscular strength, and balance in underserved adult cancer survivors > 60 years of age and/or those of any age residing at a rural address. Also, to determine if increasing PA will increase quality of life (QOL), as measured by physical functioning and fatigue, in underserved cancer survivors >60 years of age and/or those of any age residing at a rural address.

NCT ID: NCT05988762 Completed - Healthy Clinical Trials

Supramaximal Walkouts and Back Squat Performance

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized, counterbalanced, crossover study is to determine the effectiveness of performing a supramaximal walkout on enhancing subsequent back squat performance in trained lifters. The main question we aim to answer is whether bar velocity, power output, perceived exertion, and muscle activation are altered when performing the back squat exercise after a supramaximal walkout. On the first visit, participants will be informed of the study protocols before providing oral and written informed consent. Afterwards, participants will complete maximum voluntary isometric contraction (MVIC) testing for the quadriceps and gluteus maximus muscle groups to generate a normalization for the electromyography (EMG) measurements. During the second visit, participants will perform a 1RM back squat. The third and fourth visits will be the experimental visits, where they will perform either a supramaximal (110% 1RM) or submaximal (control; 30% 1RM) walkout. A set of 1 back squat at 92.5% 1RM will be performed prior to the walkout to serve as a baseline, then 3 sets of 1 at 92.5% 1RM will be performed afterwards.

NCT ID: NCT05988710 Recruiting - Pain Clinical Trials

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia

Start date: October 19, 2023
Phase: Phase 4
Study type: Interventional

The goal of this study is to compare the abuse potential of low-dose equianalgesic buccal buprenorphine to a commonly used full mu opioid receptor (MOR) agonist in a highly controlled experimental setting. This is a translational study in which healthy participants are phenotyped for psychosocial and Opioid-Use-Disorder-risk-related metrics. In a within-subjects crossover design, 60 participants will receive a standard postoperative oral oxycodone dose (10 mg), placebo, and 3 different doses of buccal buprenorphine across 5 separate sessions. Quantitative Sensory Testing (QST) will be used to evaluate alterations in pain responsiveness relative to placebo across buprenorphine doses and oxycodone, and will compare abuse potential (indexed by the standard FDA drug liking metric) following equianalgesic doses of the two drugs.

NCT ID: NCT05988658 Recruiting - Acute Kidney Injury Clinical Trials

Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients

Start date: January 5, 2024
Phase:
Study type: Observational

The study's objective is to evaluate the additive value of renal biomarkers (from blood and urine) for identifying individuals at high risk for severe acute kidney injury (AKI) above that of a novel natural language processing (NLP)-based AKI risk algorithm. The risk algorithm is based on electronic health records (EHR) data (labs, vitals, clinical notes, and test reports). Patients will enroll at the University of Chicago Medical Center and the University of Wisconsin Hospital, where the risk score will run in real time. The risk score will identify those patients with the highest risk for the future development of Stage 2 AKI and collect blood and urine for biomarker measurement over the subsequent 3 days.

NCT ID: NCT05988632 Recruiting - Clinical trials for Alcohol Use Disorder

Intranasal Insulin for Treatment of Alcohol Use Disorder

ITA
Start date: March 25, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized controlled trial (RCT), within-subject, crossover, double-blind, placebo-controlled in non-treatment-seeking individuals with Alcohol Use Disorder (AUD) (N=40, 50% female) randomized to IN insulin or placebo. In a bar laboratory setting, randomized participants will receive a single dose of IN insulin (80IU) or an IN matched placebo (0.9% Saline). Participants will undergo a cue-reactivity paradigm followed by an alcohol challenge that includes an alcohol drink designed to raise the breath alcohol content (BrAC) to 0.08g/dL.

NCT ID: NCT05988619 Active, not recruiting - Clinical trials for Major Depressive Disorder

iCBT With TMS in Patients With MDD

Start date: March 21, 2021
Phase: N/A
Study type: Interventional

Major Depressive Disorder (MDD) is a common mental health diagnosis. While there are many approaches to the treatment of MDD, current treatments of MDD often do not substantially reduce depressive symptoms among those in need of care. Prior research suggests that combining cognitive-behavioral therapy (CBT) and psychopharmacology can produce optimal treatment outcomes compared to the use of either treatment individually. Transcranial Magnetic Stimulation (TMS) is one promising brain stimulation approach used to treat MDD, especially among patients with treatment-resistant symptoms. Like psychopharmacological interventions, TMS may produce optimal treatment outcomes when paired with CBT. However, standard TMS protocols are time-intensive, typically requiring daily doctor visits for one hour of six to eight weeks. Therefore, an internet-delivered CBT protocol may augment the effects of TMS without substantially increasing patient burden. To that end, the present study assesses if a combined TMS and internet-delivered CBT protocol may produce superior treatment outcomes compared with TMS alone.

NCT ID: NCT05988606 Completed - Clinical trials for High-Intensity Interval Training

Work Rate Adjustments During a High-intensity Interval Training on a Stationary Bike in a Hot and Temperate Environment

Start date: May 12, 2021
Phase: N/A
Study type: Interventional

The goal of this repeated measures study is to evaluate acute work rate adjustments during high-intensity interval training (HIIT) in a hot and temperate environment in healthy and active adults when using target heart rate to prescribe the exercise intensity. The main questions it aims to answer are: - Will HIIT based on target heart rate in a hot environment result in increased cardiovascular (i.e., elevated recovery HR) and thermal strain compared to HIIT in a temperate environment? - Will work rate be lowered to a greater extent during HIIT in a hot environment compared to a temperate environment in order to maintain target heart rate? - Will maximal aerobic capacity (V̇O2max) decrease to a greater extent after HIIT in the heat compared to a temperate environment? Procedures: Participants will complete 5 trials on a cycle ergometer. Trial 1 (Control Visit): Participants (n = 7) will have their maximal heart rate and V̇O2max measured in a temperate environment (~22 °C, 40% RH). Experimental Trials 2-5: The order of the trials will be counterbalanced and randomly assigned to participants. - 15TEMP: Participants will cycle at 70% of their maximum heart rate for 8 minutes as a warm-up, followed by one round of HIIT. The HIIT protocol consists of 4 minutes at 90% of maximum heart rate followed by 3 minutes at 70% of maximum heart rate, totaling 15 minutes, in a temperate environment (~22 °C, 40% RH). After the HIIT session, a graded exercise test will measure V̇O2max. - 15HEAT: Similar to 15TEMP, but participants will perform the HIIT protocol in a hot environment (~35 °C, 40% RH). - 43TEMP: Participants will cycle at 70% of their maximum heart rate for 8 minutes as a warm-up, followed by the HIIT protocol repeated four times (4 minutes at 90% of maximum heart rate and 3 minutes at 70% of maximum heart rate), totaling 43 minutes, in a temperate environment (~22 °C, 40% RH). - 43HEAT: Similar to 43TEMP, but participants will perform the HIIT protocol in a hot environment (~35 °C, 40% RH).

NCT ID: NCT05988515 Recruiting - Clinical trials for Speech Sound Disorder

AI-Assisted Treatment for Residual Speech Sound Disorders

Start date: March 12, 2024
Phase: N/A
Study type: Interventional

The goal of this randomized-controlled trial is to determine how artificial intelligence-assisted home practice may enhance speech learning of the "r" sound in school-age children with residual speech sound disorders. All child participants will receive 1 speech lesson per week, via telepractice, for 5 weeks with a human speech-language clinician. Some participants will receive 3 speech sessions per week with an Artificial Intelligence (AI)-clinician during the same 5 weeks as the human clinician sessions (CONCURRENT treatment order group), whereas others will receive 3 speech sessions per week with an AI-clinician after the human clinician sessions end (SEQUENTIAL treatment order group.

NCT ID: NCT05988489 Recruiting - Suicidal Ideation Clinical Trials

Dynamic Deconstructive Psychotherapy Versus Brief Intervention and Contact for Suicidal Adolescents and Young Adults

Start date: October 25, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to assess whether 6 months of treatment with Dynamic Deconstructive Psychotherapy (DDP) is more effective for reducing thoughts of suicide in suicidal adolescents and young adults than usual care in the community supplemented with Brief Intervention and Contact (BIC). DDP and BIC are two evidence-based practices shown to be more effective than usual care at reducing suicidality. Participants will be randomly assigned to receive DDP treatment with safety planning and optional medication management or BIC treatment with safety planning and optional medication management. Participants in both groups will receive the assigned treatment at SUNY Upstate Medical University's Psychiatry High Risk Program (PHRP). Each participant is anticipated to take part in this trial for up to one year.